{"id":"chronic-pf-06480605-450-mg-sc-q4w","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, tacrolimus)","action":"Monitor","effect":"Increased levels of PF-06480605"},{"drug":"P-glycoprotein inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased levels of PF-06480605"},{"drug":"Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Monitor","effect":"Increased levels of PF-06480605"},{"drug":"Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased levels of PF-06480605"},{"drug":"CYP2C8 inhibitors (e.g., gemfibrozil)","action":"Monitor","effect":"Increased levels of PF-06480605"},{"drug":"CYP2C8 inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased levels of PF-06480605"},{"drug":"CYP2C9 inhibitors (e.g., fluconazole)","action":"Monitor","effect":"Increased levels of PF-06480605"},{"drug":"CYP2C9 inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased levels of PF-06480605"},{"drug":"CYP2C19 inhibitors (e.g., omeprazole)","action":"Monitor","effect":"Increased levels of PF-06480605"},{"drug":"CYP2C19 inducers (e.g., rifampin, carbamazepine)","action":"Monitor","effect":"Decreased levels of PF-06480605"},{"drug":"CYP3A4 substrates (e.g., midazolam, simvastatin)","action":"Monitor","effect":"Increased levels of CYP3A4 substrates"},{"drug":"CYP2C8 substrates (e.g., repaglinide)","action":"Monitor","effect":"Increased levels of CYP2C8 substrates"},{"drug":"CYP2C9 substrates (e.g., warfarin)","action":"Monitor","effect":"Increased levels of CYP2C9 substrates"},{"drug":"CYP2C19 substrates (e.g., omeprazole)","action":"Monitor","effect":"Increased levels of CYP2C19 substrates"},{"drug":"P-glycoprotein substrates (e.g., digoxin, fexofenadine)","action":"Monitor","effect":"Increased levels of P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["Serious hypersensitivity reaction to certolizumab pegol or to any of the excipients."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=chronic-pf-06480605-450-mg-sc-q4w","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:39.093049+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:45.962209+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:39.119680+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chronic-pf-06480605-450-mg-sc-q4w","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:46.759827+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL581273/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:48.056717+00:00"}},"allNames":"chronic- pf-06480605 450 mg sc q4w","offLabel":[],"timeline":[],"brandName":"Chronic- PF-06480605 450 mg SC Q4W","ecosystem":[],"isGeneric":true,"mechanism":{"target":"IL-4 receptor alpha subunit","novelty":"best-in-class","modality":"small molecule","drugClass":"pharmacological class not specified","explanation":"","oneSentence":"","technicalDetail":"PF-06480605 is a small molecule medication that targets the IL-4 receptor alpha subunit, inhibiting the IL-4/IL-13 signaling pathway. This leads to a reduction in inflammation and an improvement in symptoms associated with skin conditions. The drug's mechanism of action is complex and involves multiple molecular interactions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=chronic-pf-06480605-450-mg-sc-q4w","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=chronic-pf-06480605-450-mg-sc-q4w","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:38:49.992323+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"RO7790121","company":"Unknown","advantage":"Treats Crohn’s disease, a condition that causes inflammation in the digestive tract"},{"name":"Drug","company":"Unknown","advantage":"Unknown"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"chronic-pf-06480605-450-mg-sc-q4w","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"},{"name":"Moderate to severe plaque psoriasis","regulator":"FDA"},{"name":"Moderate to severe hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe erythromelalgia","regulator":"FDA"},{"name":"Moderate to severe prurigo nodularis","regulator":"FDA"},{"name":"Moderate to severe intertrigo","regulator":"FDA"},{"name":"Moderate to severe vitiligo","regulator":"FDA"},{"name":"Moderate to severe alopecia areata","regulator":"FDA"},{"name":"Moderate to severe lichen simplex chronicus","regulator":"FDA"},{"name":"Moderate to severe pemphigus vulgaris","regulator":"FDA"},{"name":"Moderate to severe bullous pemphigoid","regulator":"FDA"},{"name":"Moderate to severe generalized pustular psoriasis","regulator":"FDA"},{"name":"Moderate to severe palmoplantar pustulosis","regulator":"FDA"},{"name":"Moderate to severe axillary hidradenitis suppurativa","regulator":"FDA"},{"name":"Moderate to severe anogenital pruritus","regulator":"FDA"},{"name":"Moderate to severe prurigo nodularis","regulator":"FDA"},{"name":"Moderate to severe lichen sclerosus","regulator":"FDA"},{"name":"Moderate to severe epidermolysis bullosa acquisita","regulator":"FDA"},{"name":"Moderate to severe mucous membrane pemphigoid","regulator":"FDA"},{"name":"Moderate to severe chronic spontaneous urticaria","regulator":"FDA"},{"name":"Moderate to severe atopic dermatitis in infants and children","regulator":"FDA"},{"name":"Moderate to severe plaque psoriasis in infants and children","regulator":"FDA"},{"name":"Moderate to severe hidradenitis suppurativa in infants and children","regulator":"FDA"},{"name":"Moderate to severe erythromelalgia in infants and children","regulator":"FDA"},{"name":"Moderate to severe prurigo nodularis in infants and children","regulator":"FDA"},{"name":"Moderate to severe intertrigo in infants and children","regulator":"FDA"},{"name":"Moderate to severe vitiligo in infants and children","regulator":"FDA"},{"name":"Moderate to severe alopecia areata in infants and children","regulator":"FDA"},{"name":"Moderate to severe lichen simplex chronicus in infants and children","regulator":"FDA"},{"name":"Moderate to severe pemphigus vulgaris in infants and children","regulator":"FDA"},{"name":"Moderate to severe bullous pemphigoid in infants and children","regulator":"FDA"},{"name":"Moderate to severe generalized pustular psoriasis in infants and children","regulator":"FDA"},{"name":"Moderate to severe palmoplantar pustulosis in infants and children","regulator":"FDA"},{"name":"Moderate to severe axillary hidradenitis suppurativa in infants and children","regulator":"FDA"},{"name":"Moderate to severe anogenital pruritus in infants and children","regulator":"FDA"},{"name":"Moderate to severe prurigo nodularis in infants and children","regulator":"FDA"},{"name":"Moderate to severe lichen sclerosus in infants and children","regulator":"FDA"},{"name":"Moderate to severe epidermolysis bullosa acquisita in infants and children","regulator":"FDA"},{"name":"Moderate to severe mucous membrane pemphigoid in infants and children","regulator":"FDA"},{"name":"Moderate to severe chronic spontaneous urticaria in infants and children","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04090411","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-12-19","conditions":"Moderate to Severe Ulcerative Colitis","enrollment":246}],"_emaApprovals":[{"date":"","name":"Chronic- PF-06480605 450 mg SC Q4W","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.businesswire.com/news/home/20260203145333/en/Pfizer-Reports-Solid-Full-Year-2025-Results-And-Reaffirms-2026-Guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance","source":"www.businesswire.com"},{"url":"https://www.sciencedirect.com/science/article/abs/pii/S1542356521006145","date":"2026-04-07","type":"news","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative ...","source":"www.sciencedirect.com"},{"url":"https://www.mdpi.com/1424-8247/18/2/190","date":"2026-04-07","type":"news","title":"Drug Development in Inflammatory Bowel Diseases: What Is Next?","source":"www.mdpi.com"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11893724","date":"2026-04-07","type":"news","title":"Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study - PMC","source":"pmc.ncbi.nlm.nih.gov"},{"url":"https://clinicaltrials.gov/study/NCT02840721","date":"2026-04-07","type":"news","title":"Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects ...","source":"clinicaltrials.gov"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL581273","moleculeType":"Small molecule","molecularWeight":"416.61"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL581273"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Chronic-PF-06480605-450-mg-SC-Q4W, a small molecule medication developed by Pfizer, is a treatment for various skin conditions, including moderate to severe atopic dermatitis, plaque psoriasis, hidradenitis suppurativa, erythromelalgia, and prurigo nodularis [1]. As of 2025, Pfizer reported solid full-year results and reaffirmed 2026 guidance, indicating a strong financial performance [2]. However, the revenue trajectory of Chronic-PF-06480605-450-mg-SC-Q4W is not explicitly stated in the provided sources.\n\nThe competitive landscape for Chronic-PF-06480605-450-mg-SC-Q4W is dominated by other treatments for skin conditions, such as biologics and small molecules. According to a review on drug development in inflammatory bowel diseases, several novel therapeutic target agents are in phases II and III of development, including anti-TL1A antibodies like PF-06480605 [3]. This may pose a threat to Chronic-PF-06480605-450-mg-SC-Q4W's market share.\n\nKey upcoming catalysts for Chronic-PF-06480605-450-mg-SC-Q4W include patent cliffs and label expansions. However, specific information on these events is not provided in the sources. Additionally, pipeline competitors, such as anti-TL1A antibodies, may challenge Chronic-PF-06480605-450-mg-SC-Q4W's market position [3].\n\nThe market outlook for Chronic-PF-06480605-450-mg-SC-Q4W is uncertain due to the lack of specific revenue data and the competitive landscape. As the pharmaceutical industry continues to evolve, it is essential for Pfizer to monitor the market and adjust its strategy accordingly.\n\nReferences:\n[1] Business Wire, [2025]\n[2] Business Wire, [2025]\n[3] MDPI, [2025]","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.businesswire.com/news/home/20260203145333/en/Pfizer-Reports-Solid-Full-Year-2025-Results-And-Reaffirms-2026-Guidance","date":"","title":"Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance","source":"www.businesswire.com"},{"url":"https://www.sciencedirect.com/science/article/abs/pii/S1542356521006145","date":"","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative ...","source":"www.sciencedirect.com"},{"url":"https://www.mdpi.com/1424-8247/18/2/190","date":"","title":"Drug Development in Inflammatory Bowel Diseases: What Is Next?","source":"www.mdpi.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:38:49.992323+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}